Most testosterone treatments solve one problem by creating another: they raise serum testosterone but suppress the body's own hormone signal, shrinking the testes and cutting off sperm production. Enclomiphene was built around the opposite idea — a once-daily oral compound that, in trials, pushed the body to make more of its own testosterone while leaving fertility intact. It is the trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM), and its clearest trial evidence is exactly that split result: testosterone up, sperm counts preserved.
Research-context information only. Enclomiphene is an investigational drug not approved by the FDA. Protocols, doses, and reactions reported below come from published clinical trials and self-reported community sources. This article reports what has been documented, not what should be done. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.
Enclomiphene completed Phase 3 development as an oral candidate for secondary hypogonadism but was never approved, so the material on the research-chemical market is sold for laboratory use only. The clinical record behind it, however, is unusually specific for a compound in this category — several controlled trials measured testosterone, LH, FSH, and sperm counts head-to-head against topical testosterone. The benefits below are ordered strongest-evidence first.
How Enclomiphene Works
The hypothalamic-pituitary-gonadal (HPG) axis runs on negative feedback: when the brain senses estrogen (some of which is aromatized from testosterone), it dials down gonadotropin-releasing hormone, and the pituitary releases less luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Enclomiphene blocks estrogen receptors at the hypothalamus and pituitary, so the brain no longer "sees" that feedback. LH and FSH rise, and the testes are stimulated to produce more endogenous testosterone and to keep spermatogenesis running.
That mechanism is why enclomiphene behaves so differently from testosterone therapy — it works one level upstream, at the signal rather than the gland. For where to source it and how vendors format it, see the enclomiphene buying guide.
Key Benefits at a Glance
Trial-Reported Benefit
Evidence level
Source
Raises endogenous testosterone in secondary hypogonadism
Human Phase 3
Kim 2016
Preserves sperm counts vs testosterone gel
Human clinical
Kaminetsky 2013 / Kim 2016
Lifts LH and FSH (restores the upstream signal)
Human PK/PD
Wiehle 2013
Oral, once-daily route
Human PK/PD
Wiehle 2013
Purified antagonist isomer vs clomiphene
Pharmacology
Wiehle 2013
Raises Endogenous Testosterone
The most robust evidence for enclomiphene is that it raises the body's own testosterone. In two parallel Phase 3 studies (Kim and colleagues, 2016) of overweight men with secondary hypogonadism, mean total testosterone climbed from a baseline near 205 ng/dL into the ~410-450 ng/dL range on daily oral enclomiphene — comparable to the testosterone-gel comparator. Earlier pharmacodynamic work (Wiehle and colleagues, 2013) reported significant total-testosterone increases after only two weeks of oral dosing, and those increases were accompanied by rises in LH and FSH, confirming the effect came from a reawakened upstream signal rather than from hormone added from outside.
The distinction matters because it defines the whole compound: trial data describe enclomiphene as restoring testosterone production, not replacing it.
750mg · sold research-use-only · we may earn a commission
Preserves Sperm Counts Where Testosterone Gel Doesn't
This is enclomiphene's signature trial finding. In a proof-of-principle study (Kaminetsky and colleagues, 2013) comparing oral enclomiphene with testosterone gel in men with secondary hypogonadism, both treatments reached similar total-testosterone levels at six months — but only enclomiphene raised LH and FSH, and only enclomiphene raised sperm counts, reported in seven of seven men at three months and six of six at six months. The gel group did not show the same recovery.
The Phase 3 program echoed it at scale: across Kim and colleagues (2016), sperm concentration rose modestly in the enclomiphene arms while it fell by roughly 33-57% in the testosterone-gel arms. For men who want their testosterone raised without trading away fertility, that divergence is the entire argument for the compound.
Restores the Upstream Hormone Signal
Because enclomiphene acts at the hypothalamus and pituitary, its effect shows up first as higher gonadotropins. Wiehle and colleagues (2013) documented that oral dosing raised LH and FSH alongside total testosterone, and a randomized Phase 2 trial (Wiehle and colleagues, 2014) reported the same coordinated response — testosterone up, gonadotropins up, oligospermia prevented. Raising LH and FSH is the mechanistic fingerprint that separates a SERM like enclomiphene from exogenous testosterone, which drives those same hormones toward zero.
An Oral, Once-Daily Route
Unlike injectable or transdermal testosterone, enclomiphene is taken as an oral capsule. The pharmacokinetic work (Wiehle and colleagues, 2013) characterized it as orally active with a pharmacology suited to once-daily dosing, and every subsequent trial administered it that way. Reviews of the compound (Rodriguez and colleagues, 2016) framed this oral, fertility-sparing route as its main point of differentiation from standard testosterone therapy for secondary hypogonadism.
How Enclomiphene Compares
Enclomiphene is the trans-isomer of clomiphene citrate. Clomiphene itself is a roughly 62:38 mixture of zuclomiphene — the longer-lasting, more estrogenic cis-isomer — and enclomiphene, the estrogen-receptor antagonist that clears the body faster. Pharmacokinetic analysis (Wiehle and colleagues, 2013) describes enclomiphene as the component responsible for the gonadotropin-driving effect, without the accumulating zuclomiphene fraction that builds up over time on clomiphene. Isolating the antagonist isomer was the original rationale for developing enclomiphene as a distinct compound.
Against testosterone therapy the difference is directional rather than one of degree: testosterone products supply the hormone and suppress the axis; enclomiphene raises the signal and preserves it. Enclomiphene is investigational and unapproved; testosterone is available as approved finished pharmaceutical products. For a side-by-side treatment comparison, the sibling TRT resource covers enclomiphene vs TRT in depth.
Who Enclomiphene Is Studied In
Best documented in: overweight and otherwise healthy men with secondary hypogonadism (low testosterone from an insufficient pituitary signal, not primary testicular failure).
Also studied in: men who want to raise testosterone while preserving spermatogenesis and testicular function.
Community use: post-cycle and testosterone-support protocols, where the evidence is self-reported rather than from controlled trials.
Bac Water Made for Peptides50% off
Don't risk a $300 peptide on generic bac water.
Most cloudy reconstitutions trace back to one thing — and it isn't the peptide. Sterile, non-pyrogenic, 0.9% benzyl alcohol — formulated for peptide reconstitution, not repackaged from generic stock.
✓ 0.9% benzyl alcohol✓ Made for peptides✓ 30 mL multi-dose
What did trials report about enclomiphene and testosterone?
In two parallel Phase 3 studies (Kim et al., 2016), overweight men with secondary hypogonadism and a baseline total testosterone near 205 ng/dL saw mean levels rise to roughly 446 and 413 ng/dL on daily oral enclomiphene. Earlier pharmacodynamic work (Wiehle et al., 2013) reported significant total-testosterone increases after just two weeks of oral dosing, accompanied by rises in LH and FSH. The pattern is consistent: enclomiphene raises the body's own testosterone by lifting the upstream gonadotropin signal.
How does enclomiphene differ from testosterone therapy?
Testosterone therapy adds hormone from outside and suppresses the body's own LH, which shuts down intratesticular testosterone and sperm production. Enclomiphene works in the opposite direction: it blocks estrogen's negative feedback at the hypothalamus and pituitary, so LH and FSH rise and the testes are stimulated to make more of their own testosterone. In trials it raised testosterone comparably to testosterone gel while preserving sperm counts the gel reduced (Kim 2016, Kaminetsky 2013).
What is the difference between enclomiphene and clomiphene?
Clomiphene citrate is a mixture of two isomers: zuclomiphene (the longer-lasting, more estrogenic cis-isomer) and enclomiphene (the trans-isomer, an estrogen-receptor antagonist that clears the body faster). Enclomiphene was developed as the isolated antagonist isomer, and pharmacokinetic work (Wiehle et al., 2013) describes it as the component that drives the gonadotropin and testosterone response without the accumulating zuclomiphene fraction.
Did enclomiphene preserve fertility in trials?
Yes, in the reported studies. In a proof-of-principle trial (Kaminetsky et al., 2013), enclomiphene raised sperm counts in seven of seven men at three months and six of six at six months, while testosterone gel did not. Across the Phase 3 program (Kim et al., 2016), sperm concentration rose modestly in the enclomiphene groups while it fell 33-57% in the testosterone-gel groups. Preserving spermatogenesis while raising testosterone is enclomiphene's defining trial finding.
Is enclomiphene FDA-approved?
No. Enclomiphene completed Phase 3 trials for secondary hypogonadism but was never approved by the FDA, so no finished pharmaceutical product exists. The material sold by research-chemical vendors is labeled not for human consumption. This article reports what published trials documented, not medical advice.
Kaminetsky J, Werner M, Fontenot G, Wiehle RD. Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel. J Sex Med. 2013;10(6):1628-1635. PMID: 23530575
Wiehle RD, Fontenot GK, Willett MS, et al. Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism: a pharmacodynamic and pharmacokinetic study. BJU Int. 2013;112(8):1188-1200. PMID: 23875626
Wiehle RD, Fontenot GK, Wike J, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertil Steril. 2014;102(3):720-727. PMID: 25044085
Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117(4):677-685. PMID: 26496621
Rodriguez KM, Pastuszak AW, Lipshultz LI. Enclomiphene citrate for the treatment of secondary male hypogonadism. Expert Opin Pharmacother. 2016;17(11):1561-1567. PMID: 27337642
